Home » Atopic Dermatitis (AD) Treatment Market

Atopic Dermatitis (AD) Treatment Market By Drug Type (Anti-Inflammatory Agents, Antihistamines, Immunomodulators, Interleukin Inhibitors, Topical Phosphodiesterase-4 (PDE-4) Inhibitors, Antiviral Agents, Antibiotics) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Price: $4999

Published: | Report ID: 2367 | Report Format : PDF

Market Insights

Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. The atopic dermatitis treatment market is rapidly growing due to factors such as the growing prevalence of AD, significant unmet needs, and promising pipeline molecules that would fuel the market’s growth.

The report titled “Atopic Dermatitis (AD) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall Atopic Dermatitis (AD) treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

Geographically, the global AD treatment market is studied for the following regional markets:

      • North America
        • U.S.
        • Canada
      • Europe
        • Germany
        • France
        • Italy
        • U.K.
        • Russia
        • Rest of Europe
      • Asia-Pacific
        • India
        • China
        • Japan
        • Rest of Asia-Pacific
      • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
      • Middle East and Africa
        • GCC Countries
        • South Africa
        • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global AD treatment market. Pipeline analysis of AD treatment molecules and global epidemiology data have been included in the report. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global AD treatment market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global AD treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global AD treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug type, the global atopic dermatitis (AD) treatment market is segmented as follows:

      • Anti-inflammatory agents
      • Corticosteroids
      • Calcineurin Inhibitors
      • Antihistamines
      • Immunomodulators
      • Interleukin Inhibitors
      • Topical Phosphodiesterase-4 (PDE-4) Inhibitors
      • Antiviral agents
      • Antibiotics

Atopic dermatitis (AD), also known as atopic eczema, is an inflammatory disease of the skin in which the skin becomes extremely itchy and inflamed, causing redness, swelling, and vesicle formation. There is no cure for AD, but medications are used to relieve itching and prevent new outbreaks. It is studied that, currently, anti-inflammatory agents hold the largest market share in the global atopic dermatitis treatment market.

Among the considered anti-inflammatory segments, corticosteroids are a major revenue-generating segment as these are preferred as first-line treatments after the failure of skin care and moisturizers due to their effectiveness. During the forecast period, new product launches are expected to drive the AD treatment market’s growth. Pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab, and tralokinumab are expected to show AD treatment market growth during the forecast period. However, adverse effects associated with medication and poor treatment compliance in some countries may negatively impact the AD treatment market’s growth.

For the purpose of this study, the global atopic dermatitis (AD) treatment market is categorized into three segments:

      • North America
      • Europe
      • Asia Pacific
      • Latin America (LATAM)
      • Middle East and Africa (MEA)

Atopic dermatitis (AD) is a chronic, inflammatory disease of the skin characterized by dry, itchy skin. The prevalence of AD is approximately 15–20% in children and 1–3% in adults worldwide, and the incidence has increased by 2–3 folds during the past decade in industrialized countries. Among the considered geographical segments, North America was the major revenue-generating segment in the base year 2016. Some factors, such as the increase in the prevalence of AD, higher treatment awareness, the swift adoption of novel medications, and better reimbursement policies in healthcare systems, are the prime contributors to the dominance of the North American atopic dermatitis market. Expenditure on healthcare is highest in the United States as compared to other nations, which is another factor contributing to the growth of the AD treatment market.

According to the American Academy of Dermatology, approximately 10 to 20 percent of children in the United States develop atopic dermatitis; AD affects more than 28 million people of all ages in the United States alone. It is estimated that Asia Pacific will show the highest AD treatment market growth during the forecast period due to increasing healthcare awareness among the general patient population, developing economic conditions, a growing number of investments, and the partnering of key players with local manufacturers.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Atopic Dermatitis (AD) Treatment Market Snapshot
2.2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
2.3 Global Atopic Dermatitis (AD) Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Atopic Dermatitis (AD) Treatment Market Analysis
3.1 Global Atopic Dermatitis (AD) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Atopic Dermatitis (AD) Treatment Drugs
3.4 Global Epidemiology of Atopic Dermatitis (AD)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Atopic Dermatitis (AD) Treatment Market

Chapter 4 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
4.3 Top 3 Countries
4.4 Anti-inflammatory agents
4.4.1 Corticosteroids
4.4.2 Calcineurin Inhibitors
4.5 Antihistamines
4.6 Immunomodulators
4.7 Interleukin Inhibitors
4.8 Topical Phosphodiesterase-4 (PDE-4) Inhibitors
4.9 Antiviral agents
4.10 Antibiotics

Chapter 5 Global Atopic Dermatitis (AD) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AbbieVie Inc.
6.2 Encore Dermatology Inc.
6.3 F. Hoffmann-La Roche AG
6.4 Glaxosmithkline plc.
6.5 LEO Pharma A/S
6.6 Medimmune LLC. (Astrazeneca)
6.7 Novartis AG
6.8 Pfizer Inc.
6.9 Regeneron Pharmaceuticals Inc.
6.10 Sanofi S.A.
6.11 Valeant Pharmaceuticals Inc.

List of Figures

FIG. 1 Atopic Dermatitis (AD) Treatment Market: Research Methodology
FIG. 2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2016 (US$ Bn)
FIG. 3 Global Atopic Dermatitis (AD) Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Atopic Dermatitis (AD) Treatment Market, by Drug type, 2016
FIG. 6 Global Corticosteroids Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Calcineurin Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Antihistamines Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Immunomodulators Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Interleukin Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 11 Global Topical Phosphodiesterase-4 (PDE-4) Inhibitors Market, 2015 – 2025 (US$ Bn)
FIG. 12 Global Antiviral agents Market, 2015 – 2025 (US$ Bn)
FIG. 13 Global Antibiotics Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Atopic Dermatitis (AD) Treatment Market
TABLE 2 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Atopic Dermatitis (AD) Treatment Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Anti-inflammatory agents in Atopic Dermatitis (AD) Treatment, 2015 – 2025 (US$ Bn)
TABLE 5 Global Atopic Dermatitis (AD) Treatment Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 6 North America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 7 North America Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 8 Europe Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 9 Europe Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 11 Asia Pacific Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 12 Latin America Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 13 Latin America Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 14 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
TABLE 15 Middle East and Africa Atopic Dermatitis (AD) Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 AbbieVie Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 17 Encore Dermatology Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 18 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 19 Glaxosmithkline plc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 20 LEO Pharma A/S: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 21 Medimmune LLC. (Astrazeneca): Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 22 Novartis AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 23 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 24 Regeneron Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 25 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
TABLE 26 Valeant Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Atopic Dermatitis Treatment Market?

The market for Atopic Dermatitis Treatment Market is expected to reach USD$ 7.66 Bn in 2025.

What is the Atopic Dermatitis Treatment Market CAGR?

The Atopic Dermatitis Treatment Market is expected to see significant CAGR growth over the coming years, at 7.4%.

What is the Forecast period considered for Atopic Dermatitis Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Atopic Dermatitis Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

AbbieVie Inc.,Encore Dermatology Inc.,F. Hoffmann-La Roche AG,Glaxosmithkline plc.are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN